BHVN vs BIIB
BHVN: Biohaven is a biopharmaceutical firm developing a diverse pipeline of innovative therapies for complex diseases in neuroscience, immunology, obesity, and oncology. BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA.
Side-by-side fundamentals
| Metric | BHVN | BIIB | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $13.85 | $216.78 | |
| Market cap as of 2026-08-24 | $2.1B | $32.0B | |
| P/E as of 2026-08-24 | n/a | 37.20 | |
| PEG as of 2026-08-24 | n/a | 10.99 | |
| Net margin as of 2026-08-24 | n/a | +8.3% | |
| Gross margin as of 2026-08-24 | n/a | +74.0% | |
| Operating margin as of 2026-08-24 | n/a | +10.9% | |
| ROE as of 2026-08-24 | -450.0% | +4.5% | BIIB higher |
| ROA as of 2026-08-24 | -138.0% | +2.8% | BIIB higher |
| Debt / equity as of 2026-08-24 | 1.87 | 0.43 | BIIB lower |
| Revenue growth (YoY) as of 2026-08-24 | n/a | +0.3% | |
| Revenue CAGR (3y) SEC XBRL | n/a | -0.9% | |
| Beta as of 2026-08-24 | 3.09 | 0.09 | |
| 1-year return as of 2026-08-21 close | -5.7% | +55.8% | BIIB higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.